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factorial syndrome characterized by progressive loss of 
skeletal muscle mass with or without loss of fat mass that 
cannot be reversed by conventional nutritional support. 
The highest prevalence is seen in patients suffering from 
gastrointestinal and pancreatic adenocarcinoma with 
80–90% incidence followed by prostate and lung cancer3. 
Malnutrition is the most common secondary diagnosis in 
cancer patients4. It is present in 8–88 % of cancers, and up 
to 80% in the cancer of the upper gastrointestinal tract5.
Mechanisms of Cancer Cachexia
Systemic inﬂ ammation
Even patients who are eating can become malnourished 
because of speciﬁ c biochemical and metabolic changes as-
sociated with cancer. These metabolic changes impair nu-
tritional status and contribute to cancer-related malnutri-
tion, anorexia, and cachexia. Recent reviews indicate 
cachexia is even more widespread among patients with 
advanced cancer. Malnutrition places patients with cancer 
at greater risk for complications associated with surgery, 
Introduction
In the year 2011, an international consensus deﬁ ned 
cancer cachexia as a multifactorial syndrome character-
ized by ongoing loss of skeletal muscle mass that cannot 
be fully reversed by conventional nutritional support and 
leads to progressive functional impairment1. An interna-
tional panel of experts on cachexia recently developed a 
classiﬁ cation system, which recognises that cachexia oc-
curs across a continuum, varying in severity and stage: 
pre-cachexia: early clinical or metabolic signs of cachexia, 
low-grade weight loss, which may progress to cachexia, 
cachexia: weight loss >5% in the last 6 months or a com-
bination of >2% weight loss with low muscle or low BMI, 
and refractory cachexia: occurs close to death due to rap-
idly progressing disease, which is unresponsive to anti-
cancer therapy2–4. Diagnostic criteria include weight loss 
greater than 5% over the past 6 months, weight loss great-
er than 2% in individuals with body mass index (BMI) less 
than 20 kg/m2, or evidence of sarcopenia with any degree 
of weight loss greater than 2%. »Cancer anorexia-cachexia 
syndrome« (CACS) and usually consists of a combination 
of anorexia, tissue wasting, malnutrition, weight loss and 
loss of compensatory increase in feeding. CACS is a multi-
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A B S T R A C T
Cachexia is deﬁ ned as an unintended loss of stable weight exceeding 10%. Patients with advanced cachexia express 
anorexia, early satiety, severe weight loss, weakness, anemia, and edema. Anorexia represents the result of a failure of the 
usual appetite signals whereas cachexia is the debilitating state of involuntary weight loss. This syndrome, referred to as 
the »cancer anorexia-cachexia syndrome« (CACS) and usually consists of a combination of anorexia, tissue wasting, 
malnutrition, weight loss and loss of compensatory increase in feeding. CACS represents the result of a complex interac-
tion between cancer growth and host response and is associated with a poor response to chemotherapy and with an increase 
in drug-related toxicity. In advanced cachexia (mostly in metastatic cancer and terminally disease) any interventions with 
nutritional suplements are ineffective. Therefore, nutritional support in the reversion of tumor cachexia and in the impor-
tance of maintaining patient weight, muscle mass, quality of life, has the exceptional importance, becouse good nutri-
tional status of patients leads to the possibility of more aggressive and longer treatment and thus to longer survival.
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chemotherapy, and radiation therapy. Mechanical digestive 
abnormalities can result in a lack of appetite and reduced 
food intake5. Patients with pancreatic cancer suffer from 
pain, fatigue, nausea, dysphagia, gastroparesis, duodenal 
stenosis, pancreatic insufﬁ ciency and malabsorption, and 
constipation. Cancer cachexia is a multifactorial syndrome 
characterized by uncompensated adipose tissue and skel-
etal muscle loss in the setting of anorexia that leads to 
progressive functional impairment6. There is evidence that 
anorexia and hypercatabolism are driven by cytokines (IL-
6, TNF-alpha), circulating hormones, neuropeptides, neu-
rotransmitters, and tumor-derived factors. Elevated C 
reactive protein (CRP > 10 mg/L levels), an indirect mea-
sure of systemic inﬂ ammation, has been associated with 
cachexia and poor prognosis in pancreatic cancer patients. 
Cytokines produced by tumor cells or released by the host 
as a response to the cancer affect various pathways (central 
pathways, which are hypothalamus-mediated, and periph-
eral pathways, which involve direct lipolysis and proteoly-
sis)6. Increased cytokine expression prevents the hypo-
thalamus from responding appropriately to peripheral 
signals by persistent stimulation of anorexigenic pathways 
and inhibition of orexigenic pathways. Recent studies have 
also discovered neural invasion and abnormalities in the 
muscle microenvironment in pancreatic cancer cachexia7.
Adipose Tissue Depletion and Hypermetabolism
Zinc-a2-glycoprotein (ZAG), apolipoproteins apo C-II 
and apo C-III and glucagon-like peptide-1 (GLP-1) were 
identiﬁ ed as markers for pancreatic cancer-associated ca-
chexia syndrome. GLP-1 secretion by ileal cells is depen-
dent on the presence of nutrients in the lumen of the small 
intestine. It is a potent antihyperglycemic hormone, induc-
ing glucose-dependent stimulation of insulin secretion 
while suppressing glucagon secretion.
Many tumors secrete pro-inﬂ ammatory factors tumor 
necrosis factor alpha (TNFα), interlekin (IL-) 6 and pro-
catabolic factors ZAG. The factors released by the host as 
a antitumor immune response are interferon gamma 
(IFNγ). They are also responsible for promoting degrada-
tive pathways in skeletal muscle and adipose tissue2,5. 
Dysregulated lipid metabolism is a hallmark of cancer. 
Functions of lipids are critical in malignant tumors as 
they are necessary not only for providing the membrane 
constituents of proliferating cells but also for energetic, 
biophysical, and signaling pathways that drive tumorigen-
esis2. For example, injection of lipid-mobilizing factor from 
cachectic cancer patients promotes whole body fatty acid 
oxidation in mice and cachexia5.
Protein degradation and Muscle Atrophy
Cachexia-related muscle wasting results from a distur-
bance of the tightly regulated balance of muscle protein 
breakdown and synthesis5. Some studies suggest that pro-
teolysis inducinf factor (PIF) mediated protein degrada-
tion may involve the ubiquitin-proteasome proteolytic 
pathway. PIF has also been shown to induce total protein 
degradation and myosin depletion while actin levels re-
main unchanged. The mechanism for transcription factor 
NFκB activation by PIF is not fully understood. Protein 
degradation is thought to be mediated by the activation of 
NFκB. A recent study identifying serum proteins involved 
in pancreatic cancer cachexia identiﬁ ed ZAG as a possible 
marker. ZAG not only increases lipid mobilization through 
various pathways but it also increases substrate utilization 
and activates mitochondrial oxidative pathways in brown 
adipose tissue resulting in lipolysis, increased energy ex-
penditure, and hypercatabolism. There also is evidence that 
cachexia-associated insulin resistance could result in in-
creased protein degradation of skeletal muscle8.
Management of Cancer Cachexia
Clinical management of cachexia is currently limited 
and complex. The current treatment strategies are based 
on the following factors: oncological therapy with optimal 
control of the tumor; nutritional support; and pharmaco-
logical treatment. Since cancer cachexia is a multifacto-
rial syndrome, successful treatment will likely involve a 
multimodal approach.
Apetite stimulators
Megestrol acetate is a semi-synthetic progesterone cur-
rently used as an appetite stimulant9. When megestrol 
acetate was ﬁ rst introduced in the treatment of dissemi-
nated breast and endometrial cancer, patients developed 
weight gain and increased appetite as a side effect. The 
pharmacologic activity of megestrol acetate in appetite 
stimulation and weight gain may be related to decreased 
production and release of pro-inﬂ ammatory cytokines (IL-
6, TNF-α) and stimulation of neuropeptides in the hypo-
thalamus10. In 1993, the Food and Drug Administration 
(FDA) approved megestrol acetate for the treatment of 
cancer anorexia-cachexia syndrome. Corticosteroids are 
effective in ind. cing an increase in appetite, food intake, 
weight gain, and sense of well-being However, the effects 
are short lived (less than 4 weeks) and associated with 
long-term side effects, such as insulin resistance, ﬂ uid 
retention, steroid-induced myopathy, skin fragility, adre-
nal insufﬁ ciency, and sleep and cognitive disorders. Can-
nabinoids, dronabinol is effective in reducing nausea and 
increasing appetite with associated weight stabilization. 
A phase II trial showed that dronabinol reduced anorexia 
in 68% of patients, but 16% of patients had to suspend 
treatment due to toxicity11. Appetite stimulation appears 
to be mediated by interaction with endorphin receptors, 
interference with interlekin (IL-)1 synthesis, activation of 
cannabinoid receptors involved in the neurochemical cir-
cuit of leptin, and prostaglandin synthesis inhibition12.
Nutrition supplemets
Nutritional support, addressing the speciﬁ c needs of this 
patient group, is required to help improve prognosis, and 
reduce the consequences of cancer-associated nutritional 
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decline. Early intervention with nutritional supplementa-
tion has been shown to halt malnutrition, and may improve 
outcome in some patients. Nutritional counseling, supple-
mental feeding and pharmacological support do temporar-
ily stop weight loss and improve appetite, social life and 
quality of life. The beneﬁ cial effect of eicosapentaenoic acid 
in cancer patients is widely described especially in relation 
to its role in tumour cachexia13. It is obtained in the human 
diet by eating oily ﬁ sh or ﬁ sh oil, e.g. cod liver, herring, 
mackerel, salmon, menhaden and sardine, and various 
types of edible seaweed. Beneﬁ ts to patients included pres-
ervation of lean body mass, increased physical activity, im-
proved appetite and weight gain14–16. Recent studies describ-
ing the cancer protective effect of the omega-3 fatty acids, 
eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) have sparked a renewed interest in using these 
fatty acids for cancer prevention and treatment. EPA and 
DHA have been shown to have multiple anti-tumour actions 
that affect all of the original six essential alterations that 
dictate malignant growth. Furthermore, EPA and DHA, 
have immunomodulatory properties and have been shown 
to suppress production of pro-inﬂ ammatory cytokines, in-
cluding IL-1, TNF-a, and IL-6 by periferal blood mononu-
clear cells. DHA is also known to modulate steroid recep-
tors in human cancer cell lines10. EPA may also inhibit the 
downstream effects of Lipid mobilizing factor (LMF) and 
PIF. Supplementation based on an oral powder formula en-
riched with 1.5 g EPA during one month in cancer patients 
improved certain inﬂ ammatory parameters. Studies sug-
gest that EPA, an omega-3 fatty acid, augments weight, 
appetite, and survival in cancer-associated wasting admin-
istered alone or with megestrol acetate17. Their anticancer 
actions is implicated in various stages of cancer develop-
ment, including cell proliferation, cell survival, angiogen-
esis, inﬂ ammation, metastasis and epigenetic abnormali-
ties that are crucial to the onset and progression of cancer18. 
DHA has also been shown to modulate heat shock proteins 
that act as »chaperones« in protein: protein interactions and 
in cell membrane transport19. EPA and DHA suppress ni-
trite oxide production in macrophage cell lines in a dose 
dependant fashion20. Total parenteral nutrition is a stan-
dard component of supportive treatment in oncology units 
for patients undergoing intensive therapy. Total parenteral 
nutrition (PN) has been shown to signiﬁ cantly affect post-
operative outcomes in the severely malnourished patient 
group. It was shown that omega-3 ﬁ sh oil fat emulsion-
based parenteral nutrition alleviates the inﬂ ammatory 
reaction and reduces the rate of inﬂ ammatory complica-
tions21. In general cancer patient population, enteral formu-




Tumor cells can manage to escape the anti-tumor im-
mune responses. Revealing the underlying mechanisms 
for solid pediatric tumors could foster development of tu-
mor-speciﬁ c and immunologic anti-cancer therapies. Such 
immunological escape mechanisms could be treated phar-
macologically. Immunotherapy with lenalidomide enhanc-
ed activation of natural killer cells and inhibited their 
suppression by NFkB induced IL-6 or transforming 
growth factor-b1 within the tumor environment17. Tha-
lidomide is known to have anti-inﬂ ammatory and immu-
nomodulatory properties23. It has been shown to down-
regulate the production of TNF-a and other cytokines, 
inhibit NFkB, downregulate cyclooksigenase (COX-)2, and 
inhibit angiogenesis. Multiple small studies have demon-
strated the efﬁ cacy of thalidomide in improving appetite, 
weight gain, and sensation of well-being24.
Zync
Altered Zn metabolism may contribute to systemic in-
ﬂ ammation observed in cancer cachexia because Zn ho-
meostasis is critical for efﬁ cient immune function. Zn 
dysregulation in the pathogenesis of pancreatic cancer and 
the use of Zn therapy and Zn transporters as potential 
therapeutic targets25.
Ghrelin 
Ghrelin, a 28-amino acid peptide, was isolated from the 
human and rat stomach and identiﬁ ed in 1999 as an en-
dogenous ligand for the ghrelin receptor (GHS-R) type 1a. 
Ghrelin mediates its anorexigenic action via stimulation 
of neurons within the hypothalamus26. GHS-R is ex-
pressed in the vagus nerve. Brainstem and vagus nerve 
may contribute to the effects of ghrelin on food intake. 
Blockade of gastric vagal afferents in rats abolishes ghre-
lin-induced feeding. In neoplastic disorders, a proliferative 
effect of ghrelin has been documented as well27.
L-carnitine
Patients with pancreatic cancer may have a clinically 
relevant beneﬁ t from the inexpensive oral supplementa-
tion of L-Carnitine. L-Carnitine signiﬁ cantly improved 
the fatigue domain. Carnitine was well tolerated, and no 
drug-related adverse effects were identiﬁ ed. Intravenous 
L-carnitine treatment increased plasma carnitine concen-
trations, improved patient-assessed fatigue28.
Exercise
During cachexia muscle strength and endurance are 
dramatically reduced, limiting the ability to perform dai-
ly activities and severely affecting the patient’s quality of 
life. Different studies have emphasized that a single ther-
apy may not be completely successful in the treatment of 
cachexia. Beyond pharmacological strategies, growing 
evidence, nevertheless, shows that chronic exercise, em-
ployed as a tool to counteract systemic inﬂ ammation, may 
represent a low-cost, safe alternative for the prevention/
attenuation of cancer cachexia. Despite the well-docu-
mented capacity of chronic exercise to counteract sus-
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tained disease-related inﬂ ammation, few studies address 
the effect of exercise training in cancer cachexia29. When 
considering exercise in cancer, several factors have to be 
taken into consideration, in particular those alterations 
that could limit the capacity to perform exercise and conse-
quently the resulting beneﬁ cial or detrimental effects. Actu-
ally, many cancer patients suffer from chronic fatigue, ei-
ther from the disease itself or its treatment, the latter being 
a confounding factor that limits exercise practice.
Conclusion
Cachexia is a complex metabolic syndrome character-
ised by unintentional weight loss and depletion of skeletal 
muscle, with or without loss of adipose tissue. Cachexia is 
prevalent in chronic or end-stage cancers, and nearly half 
of all cancer patients experience some degree of weight 
loss. The original principles of nutrition care for people 
diagnosed with cancer were developed in 1979 and are 
still very relevant today. Proactive nutritional care can 
prevent or reduce the complications typically associated 
with the treatment of cancer. Two decades of exploratory 
investigation of the manifestations, meaning and manage-
ment of cancer cachexia reveal emotional and social im-
pacts for both patients and their carers. Although new 
insights to the pathogenesis of cancer cachexia have been 
gained over the past decade, the underlying mechanisms 
leading to this syndrome are not fully understood30. At the 
moment, there is no single therapy able to reverse cachex-
ia many symptoms, which include disruption of intermedi-
ary metabolism, endocrine dysfunction, compromised 
hypothalamic appetite control, and impaired immune 
function, among other.
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NUTRITIVNA POTPORA KOD BOLESNIKA S KARCINOMOM
S A Ž E T A K
Kaheksiju deﬁ niramo kao nenamjerni gubitak stjelesne težine više od 10%. Bolesnici s uznapredovalom kaheksijom 
i izrazitom anoreksijom imaju jak gubitk tjelesne težine, slabost, anemiju i edeme. Anoreksija predstavlja nastanak 
gubitka apetita dok je kaheksia stanje stalno prisutnog mršavljenja. Ovaj sindrom, nazivaju »karcinom anoreksija – ka-
heksija sindrom« i obično se sastoji od kombinacije anoreksije, slabog apetita, opće slabosti, progresivnog gubitka težine 
te gubitka kompenzacijskog povećanja hranjenja. »Karcinom anoreksija – kaheksija sindrom« je rezultat složenog 
međudjelovanja između napredovanja karcinoma i odgovora domaćina te je povezana s lošim odgovor na kemoterapiju i 
povećanjem toksičnosti povezane s lijekom. U uznapredovaloj kaheksiji (uglavnom kod metastatskog karcinoma u ter-
minalnoj fazi bolesti) bilo kakve intervencije dodavanja nutritivne potpore su ipak neuspješne. Dakle, nutritivna potporu 
potrebno je na vrijeme započeti stoga što uhranjenost tj. neuhranjenost bolesnika dovodi u pitanje primjenu agresivnije 
i dugotrajnije terapije i na taj način dulje preživljavanje onkološkog bolesnika.
